Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma
Authors
Keywords
-
Journal
International Journal of Oral Science
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-28
DOI
10.1038/s41368-020-0084-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality
- (2019) Eric C. Ko et al. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
- Abscopal Effects in Radio-Immunotherapy—Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition
- (2019) Maike Trommer et al. Frontiers in Pharmacology
- Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
- (2019) Ryan J. Sullivan et al. NATURE MEDICINE
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
- (2018) Roberta Zappasodi et al. CANCER CELL
- Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non–Small-Cell Lung Cancer: Where Do We Stand?
- (2018) Meng Qiao et al. Clinical Lung Cancer
- Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
- (2018) Rodabe N Amaria et al. LANCET ONCOLOGY
- Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy
- (2018) Brianne Cruickshank et al. Frontiers in Immunology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- VSIG-3 as a ligand of VISTA inhibits human T cell function
- (2018) Jinghua Wang et al. IMMUNOLOGY
- Chemotherapeutic Treatments Increase PD-L1 Expression in Esophageal Squamous Cell Carcinoma through EGFR/ERK Activation
- (2018) Hoi Yan Ng et al. Translational Oncology
- Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors
- (2018) Ben Tran et al. Journal for ImmunoTherapy of Cancer
- PD-L1 expression in tumor cells is an independent unfavorable prognostic factor in oral squamous cell carcinoma
- (2018) Juan C de Vicente et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
- (2018) Dan P. Zandberg et al. EUROPEAN JOURNAL OF CANCER
- Galectin-9: Diverse roles in hepatic immune homeostasis and inflammation
- (2017) Lucy Golden-Mason et al. HEPATOLOGY
- Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
- (2017) Kevin J Harrington et al. LANCET ONCOLOGY
- T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer
- (2017) Jian-Feng Liu et al. Molecular Oncology
- Systemic Therapy for Metastatic Renal-Cell Carcinoma
- (2017) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
- (2016) Jennifer E. Kim et al. CLINICAL CANCER RESEARCH
- Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
- (2016) Lucia Festino et al. DRUGS
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
- (2016) Laura Q.M. Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
- (2016) Olivier De Henau et al. NATURE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- CTLA-4+Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis
- (2015) Hyun-Bae Jie et al. CANCER RESEARCH
- Systemic Immune Activity Predicts Overall Survival in Treatment-Nai ve Patients with Metastatic Pancreatic Cancer
- (2015) M. R. Farren et al. CLINICAL CANCER RESEARCH
- The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis
- (2015) A. Wang et al. EJSO
- Immunology and Immunotherapy of Head and Neck Cancer
- (2015) Robert L. Ferris JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
- (2015) Jun Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- VISTA Regulates the Development of Protective Antitumor Immunity
- (2014) I. Le Mercier et al. CANCER RESEARCH
- LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
- (2014) F. Xu et al. CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Regulatory T Cells Control Antigen-Specific Expansion of Tfh Cell Number and Humoral Immune Responses via the Coreceptor CTLA-4
- (2014) James Badger Wing et al. IMMUNITY
- Therapeutic use of anti-CTLA-4 antibodies
- (2014) C. U. Blank et al. INTERNATIONAL IMMUNOLOGY
- The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck
- (2014) Dan P. Zandberg et al. ORAL ONCOLOGY
- Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients
- (2013) H-B Jie et al. BRITISH JOURNAL OF CANCER
- Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
- (2013) S. Lyford-Pike et al. CANCER RESEARCH
- CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma
- (2013) Cecilia Nordfors et al. EUROPEAN JOURNAL OF CANCER
- Comparison of Glioma-associated Antigen Peptide-loaded Versus Autologous Tumor Lysate-loaded Dendritic Cell Vaccination in Malignant Glioma Patients
- (2013) Robert M. Prins et al. JOURNAL OF IMMUNOTHERAPY
- Targeted Deletion of Fibrinogen Like Protein 1 Reveals a Novel Role in Energy Substrate Utilization
- (2013) Valeriy Demchev et al. PLoS One
- GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability
- (2013) D. A. Schaer et al. Cancer Immunology Research
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†
- (2012) M. Reck et al. ANNALS OF ONCOLOGY
- Immuno-oncology: understanding the function and dysfunction of the immune system in cancer
- (2012) O. J. Finn ANNALS OF ONCOLOGY
- Constitutive Clathrin-mediated Endocytosis of CTLA-4 Persists during T Cell Activation
- (2012) Omar S. Qureshi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- The TIGIT/CD226 Axis Regulates Human T Cell Function
- (2012) E. Lozano et al. JOURNAL OF IMMUNOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
- (2011) Q. Zhou et al. BLOOD
- CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation
- (2011) Xiong B Wang et al. BMC IMMUNOLOGY
- Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
- (2011) Li Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- (2011) Omid Hamid et al. Journal of Translational Medicine
- Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma
- (2010) Ryosuke Hino et al. CANCER
- Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis
- (2010) D. Pulte et al. ONCOLOGIST
- Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
- (2010) Junko Matsuzaki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells
- (2009) Wenshi Wang et al. INTERNATIONAL IMMUNOLOGY
- Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma
- (2009) Luis H. Camacho et al. JOURNAL OF CLINICAL ONCOLOGY
- Gonadectomy of male BALB/c mice increases Tim-3+ alternatively activated M2 macrophages, Tim-3+ T cells, Th2 cells and Treg in the heart during acute coxsackievirus-induced myocarditis
- (2008) Sylvia Frisancho-Kiss et al. BRAIN BEHAVIOR AND IMMUNITY
- Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma
- (2008) Y Mizukami et al. BRITISH JOURNAL OF CANCER
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started